Esprit Ma

Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014)

Ari Gnanasakthy, Carla DeMuro, Marci Clark et al. · Journal of Clinical Oncology · 2016 · 56 citations

Pharmacy, Oncology, Pharmaceutical Policy +17

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

Pankit Vachhani, Evelyn M. Flahavan, Tao Xu et al. · The Oncologist · 2022 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices

Esprit Ma, Vijayveer Bonthapally, Anita Chawla et al. · Clinical Lymphoma Myeloma & Leukemia · 2016 · 40 citations · Full text

Medicine, Geriatric Medicine, Oncology +16

Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis

Hongbo Yang, Emilie D. Duchesneau, Rebekah Foster et al. · Journal of Medical Economics · 2017 · 33 citations

Pharmacy, Neurology, Pharmacoeconomics +17

Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists

Matthew D. Galsky, Esprit Ma, Bijal Shah‐Manek et al. · Bladder Cancer · 2019 · 24 citations · Full text

Medicine, Oncology, Chemotherapy +10